Terfenadine block of sodium current in canine atrial myocytes

被引:28
|
作者
Lu, YJ
Wang, ZG
机构
[1] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada
[2] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
关键词
terfenadine; sodium current (I-Na); patch-clamp; canine atrial cells;
D O I
10.1097/00005344-199903000-00023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Terfenadine, a histamine-1 receptor antagonist, is known to have direct effects on electrical activities in the heart. Studies have demonstrated an ability of terfenadine to suppress upstroke velocity of action potential, an indication of sodium channel blockade. To clarify whether terfenadine indeed blocks sodium current (I-Na) we performed experiments to evaluate in detail the effects of terfenadine on I-Na by applying whole-cell patch-clamp techniques to canine atrial myocytes. Terfenadine produced concentration-dependent inhibition of I-Na, with a median inhibitory concentration (IC50) of 0.93 +/- 0.12 mu M. Significant effects were observed at a concentration of as low as 100 nM (similar to 15% reduction of I-Na). The effects of terfenadine on I-Na were voltage dependent, as indicated with greater inhibition at less-negative holding potentials and at more-positive test potentials. Terfenadine block ade of I-Na was characterized by an important tonic block that accounted for similar to 50% of the total block. Use-dependent block also was observed and found to contribute to 26% of the total block, and this use dependence was accentuated with longer pulse duration. Our findings suggest that terfenadine is a potent sodium channel blocker. Terfenadine blocks I-Na in both rested state and inactivated state of the channels, but preferentially interacts with the former. The I-Na-blocking property of terfenadine may contribute to its cardiac side effects in patients.
引用
收藏
页码:507 / 513
页数:7
相关论文
共 50 条
  • [21] SODIUM CURRENT OF SINGLE MYOCYTES
    LEE, KS
    KAO, RL
    BROWN, AM
    FEDERATION PROCEEDINGS, 1979, 38 (03) : 987 - 987
  • [22] Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes
    Fedida, D
    Eldstrom, J
    Hesketh, JC
    Lamorgese, M
    Castel, L
    Steele, DF
    Van Wagoner, DR
    CIRCULATION RESEARCH, 2003, 93 (08) : 744 - 751
  • [23] Adrenergic control of constitutively active acetylcholine-related potassium current in canine atrial myocytes
    Yeh, YH
    Ehrlich, JR
    Goethe, JW
    Qi, XY
    Hébert, T
    Chartier, D
    Nattel, S
    CIRCULATION, 2005, 112 (17) : U208 - U208
  • [24] Effects of sodium ferulate on the ultrarapid delayed rectifier K~+ current in human atrial myocytes
    Xiang Gao a
    bDepartment of Cardiac surgery
    JournalofNanjingMedicalUniversity, 2008, (01) : 1 - 4
  • [25] Transmembrane sodium current is different in atrial from ventricular myocytes of guinea pig heart
    Li, GR
    Shrier, A
    BIOPHYSICAL JOURNAL, 2001, 80 (01) : 189A - 189A
  • [26] Effects of 8-oxoberberine on sodium current in rat ventricular and human atrial myocytes
    Chi, JF
    Chu, SH
    Lee, CS
    Su, MJ
    CANADIAN JOURNAL OF CARDIOLOGY, 1997, 13 (11) : 1103 - 1110
  • [27] Change in late sodium current of atrial myocytes in spontaneously hypertensive rats with allocryptopine treatment
    Dong, Ying
    Huang, Yun
    Wu, Hong-lin
    Ke, Jun
    Yin, Yuan-li
    Zhu, Chao
    Li, Bin
    Li, Jie
    Gao, Lei
    Xue, Qiao
    Zhang, Jian-cheng
    Li, Yang
    CARDIOVASCULAR JOURNAL OF AFRICA, 2019, 30 (02) : 79 - 86
  • [28] Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells)
    Yang, T
    Roden, DM
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 271 (02): : H541 - H547
  • [29] Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation
    Alexander Burashnikov
    Charles Antzelevitch
    Cardiovascular Drugs and Therapy, 2013, 27 : 79 - 89
  • [30] Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation
    Burashnikov, Alexander
    Antzelevitch, Charles
    CARDIOVASCULAR DRUGS AND THERAPY, 2013, 27 (01) : 79 - 89